[go: up one dir, main page]

NO2009003I2 - Etravirin - Google Patents

Etravirin

Info

Publication number
NO2009003I2
NO2009003I2 NO2009003C NO2009003C NO2009003I2 NO 2009003 I2 NO2009003 I2 NO 2009003I2 NO 2009003 C NO2009003 C NO 2009003C NO 2009003 C NO2009003 C NO 2009003C NO 2009003 I2 NO2009003 I2 NO 2009003I2
Authority
NO
Norway
Prior art keywords
etravirine
Prior art date
Application number
NO2009003C
Other languages
English (en)
Other versions
NO2009003I1 (no
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2009003(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO2009003I1 publication Critical patent/NO2009003I1/no
Publication of NO2009003I2 publication Critical patent/NO2009003I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO2009003C 1998-11-10 2009-02-23 Etravirin NO2009003I2 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (2)

Publication Number Publication Date
NO2009003I1 NO2009003I1 (no) 2009-03-09
NO2009003I2 true NO2009003I2 (no) 2010-06-07

Family

ID=26805159

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20011696A NO318801B1 (no) 1998-11-10 2001-04-04 Hiv-replikasjonsinhiberende pyrimidiner, dens anvendelse, farmasoytiske sammensetninger inneholder dem og fremgangsmate for deres fremstilling
NO2009003C NO2009003I2 (no) 1998-11-10 2009-02-23 Etravirin
NO2021015C NO2021015I1 (no) 1998-11-10 2021-03-29 Etravirin - forlenget SPC

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20011696A NO318801B1 (no) 1998-11-10 2001-04-04 Hiv-replikasjonsinhiberende pyrimidiner, dens anvendelse, farmasoytiske sammensetninger inneholder dem og fremgangsmate for deres fremstilling

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2021015C NO2021015I1 (no) 1998-11-10 2021-03-29 Etravirin - forlenget SPC

Country Status (41)

Country Link
US (5) US6878717B2 (no)
EP (2) EP1270560B1 (no)
JP (1) JP3635238B2 (no)
KR (1) KR100658489B1 (no)
CN (1) CN1214013C (no)
AP (1) AP1683A (no)
AR (1) AR024227A1 (no)
AT (2) ATE233740T1 (no)
AU (2) AU762523C (no)
BG (1) BG65103B1 (no)
BR (1) BRPI9915552B8 (no)
CA (1) CA2350801C (no)
CY (1) CY2008021I1 (no)
CZ (1) CZ301367B6 (no)
DE (3) DE69941934D1 (no)
DK (1) DK1002795T3 (no)
EA (1) EA004049B1 (no)
EE (1) EE05086B1 (no)
ES (2) ES2193664T3 (no)
FR (1) FR09C0004I2 (no)
HK (1) HK1048817B (no)
HR (2) HRP20010161B9 (no)
HU (2) HU230394B1 (no)
ID (1) ID28376A (no)
IL (2) IL143023A0 (no)
LT (1) LTC1002795I2 (no)
LU (1) LU91528I2 (no)
MY (1) MY121108A (no)
NL (1) NL300373I2 (no)
NO (3) NO318801B1 (no)
NZ (1) NZ511116A (no)
OA (1) OA11674A (no)
PL (1) PL204427B1 (no)
PT (1) PT1002795E (no)
SI (1) SI1002795T1 (no)
SK (2) SK287269B6 (no)
TR (1) TR200101306T2 (no)
TW (1) TWI238161B (no)
UA (1) UA70966C2 (no)
WO (1) WO2000027825A1 (no)
ZA (1) ZA200103769B (no)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100658489B1 (ko) * 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CZ300712B6 (cs) 1999-09-24 2009-07-22 Janssen Pharmaceutica N. V. Cásticová farmaceutická kompozice, pevná disperze a farmaceutická dávková forma, zpusoby jejich prípravy a použití a obchodní balení s jejich obsahem
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
AU783981C (en) * 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
DK1282607T3 (en) * 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
US7039697B2 (en) * 2000-11-01 2006-05-02 Snapnames.Com Inc. Registry-integrated internet domain name acquisition system
RS94703A (sr) 2001-05-29 2007-02-05 Schering Aktiengesellschaft, Cdk-inhibirajući pirimidini, njihovo dobijanje i primena kao sredstva za lečenje
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
WO2003037891A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
MXPA04004177A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de amida como inhibidores de la glicogeno cintasa cinasa 3-beta.
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003218736B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
US7767679B2 (en) 2002-03-13 2010-08-03 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1504047B1 (en) * 2002-05-03 2007-12-12 Janssen Pharmaceutica N.V. Polymeric microemulsions
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
ES2422196T3 (es) * 2002-08-09 2013-09-09 Janssen Pharmaceutica Nv Procesos para la preparación de 4-4-4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)aminobenzonitrilo
ES2677769T3 (es) * 2002-09-20 2018-08-06 Alpharma Pharmaceuticals Llc Subunidad secuestrante y composiciones y procedimientos relacionados
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
ES2598404T3 (es) 2003-02-07 2017-01-27 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevención de infección por el VIH
US7585861B2 (en) * 2003-02-07 2009-09-08 Janssen Pharmaceutica, N.V. HIV inhibiting 1,2,4-triazines
ATE433447T1 (de) 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005011702A1 (en) 2003-07-17 2005-02-10 Tibotec Pharmaceuticals Ltd. Process for preparing particles containing an antiviral
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EA009734B1 (ru) * 2003-09-25 2008-02-28 Янссен Фармацевтика Н.В. Производные пурина, ингибирующие репликацию вич
AU2005218183B2 (en) 2004-03-02 2012-06-07 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
AU2005271161B2 (en) 2004-08-10 2011-05-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
KR20070057798A (ko) * 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
RU2405778C2 (ru) * 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. 5-гетероциклилпиримидины, ингибирующие вич
TW200626561A (en) * 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-substituted pyrimidines
CA2577588C (en) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
JP2008519073A (ja) * 2004-11-08 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
ATE523498T1 (de) 2005-01-27 2011-09-15 Tibotec Pharm Ltd Hiv-inhibierende 2-(4- cyanophenylamino)pyrimidinderivate
BRPI0607455A2 (pt) 2005-02-16 2009-09-01 Astrazeneca Ab composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
CN101119976B (zh) * 2005-02-18 2010-12-22 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物
DE602006015291D1 (de) * 2005-03-04 2010-08-19 Little Island Co Cork Hiv-inhibierende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidine
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
CN101248051B (zh) * 2005-05-26 2013-07-17 泰博特克药品有限公司 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7754773B2 (en) * 2005-10-06 2010-07-13 University Of Massachusetts Composition and synthesis of new reagents for inhibition of HIV replication
EP1945631B8 (en) 2005-10-28 2013-01-02 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
HRP20090459T1 (hr) 2006-01-19 2009-09-30 Janssen Pharmaceutica N.V. Aminofenil derivati kao novi inhibitori histonskih deacetilaza
CN101370790B (zh) 2006-01-19 2015-10-21 詹森药业有限公司 作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
CA2635015C (en) 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN101405283B (zh) 2006-03-30 2014-06-18 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
US8163745B2 (en) 2006-03-30 2012-04-24 Tibotec Pharmaceuticals Ltd. HIV inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
SI2029110T1 (sl) 2006-06-06 2012-01-31 Tibotec Pharm Ltd Z razprševanjem posušeni pripravki TMC125
RU2445077C2 (ru) 2006-06-19 2012-03-20 АЛФАРМА, Инк. Фармацевтические композиции
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
WO2008068299A2 (en) 2006-12-06 2008-06-12 Tibotec Pharmaceuticals Ltd. Hydrobromide salt of an anti-hiv compound
MX2009007006A (es) * 2006-12-29 2009-07-09 Tibotec Pharm Ltd Pirimidinas 5,6-sustituidas inhibidoras del virus de inmunodeficiencia humana.
ES2470570T3 (es) * 2006-12-29 2014-06-24 Janssen R&D Ireland Pirimidinas sustituidas en posición 6 inhibidoras del HIV
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EA029131B1 (ru) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
RU2536584C2 (ru) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR073760A1 (es) * 2008-10-03 2010-12-01 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
AU2010230344B9 (en) 2009-03-30 2014-11-27 Janssen Sciences Ireland Uc Co-crystal of etravirine and nicotinamide
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
RU2556986C2 (ru) * 2009-06-22 2015-07-20 Эмкьюар Фармасьютикалз Лимитед Способ синтеза диарилпиримидинового ненуклеозидного ингибитора обратной транскриптазы
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
JP5713367B2 (ja) 2010-06-04 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
WO2012001695A1 (en) 2010-06-28 2012-01-05 Hetero Research Foundation A process for etra virine intermediate and polymorphs of etravirine
SG187796A1 (en) 2010-08-10 2013-03-28 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
EA201390421A1 (ru) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
BR112013011600B1 (pt) 2010-11-10 2022-01-11 Genentech, Inc Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
PT2702045T (pt) 2011-04-26 2018-01-11 Mylan Laboratories Ltd Método inovador para a preparação de etravirina
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
MX361458B (es) 2011-08-23 2018-12-06 Asana Biosciences Llc Compuestos de pirimido-piridazinona y uso de los mismos.
WO2013059572A1 (en) 2011-10-19 2013-04-25 Assia Chemical Industries Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
WO2013109354A2 (en) * 2011-12-07 2013-07-25 Texas Southern University Etravirine formulations and uses thereof
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
PT2825042T (pt) 2012-03-15 2018-11-16 Celgene Car Llc Sais de um inibidor de cinases do recetor do fator de crescimento epidérmico
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US20150336900A1 (en) * 2012-10-29 2015-11-26 Biophore India Pharmaceuticals Pvt. Ltd. Process for the Synthesis of Etravirine and Its Intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
EP2934501A4 (en) 2012-12-21 2016-06-01 Verlyx Pharma Inc USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
JP2016509012A (ja) 2013-02-08 2016-03-24 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｅｒｋ阻害剤およびそれらの使用
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
WO2018201131A1 (en) 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CN114302878A (zh) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 酪氨酸激酶非受体1(tnk1)抑制剂及其用途
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
EP0172786B1 (de) * 1984-06-25 1991-01-30 Ciba-Geigy Ag Pyrimidinderivate wirksam als Schädlingsbekämpfungsmittel
ZA892407B (en) 1988-03-31 1989-11-29 Mitsubishi Chem Ind 6-substituted acyclopyrimidine nucleoside derivative and antiviral agent containing the same as active ingredient thereof
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
PL189122B1 (pl) 1995-11-23 2005-06-30 Janssen Pharmaceutica Nv Sposób wytwarzania mieszaniny stałej zawierającejjedną lub wiele cyklodekstryn, mieszanina stała ikompozycja farmaceutyczna
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
US6200977B1 (en) 1998-02-17 2001-03-13 Tularik Inc. Pyrimidine derivatives
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
ATE232521T1 (de) * 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
KR100658489B1 (ko) * 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
DK1282607T3 (en) * 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines

Also Published As

Publication number Publication date
CY2008021I2 (el) 2010-07-28
BR9915552B1 (pt) 2013-11-19
HK1048817A1 (en) 2003-04-17
NO2009003I1 (no) 2009-03-09
ES2338760T3 (es) 2010-05-12
ES2193664T3 (es) 2003-11-01
SI1002795T1 (en) 2003-10-31
PT1002795E (pt) 2003-07-31
SK287269B6 (sk) 2010-05-07
EP1270560B1 (en) 2010-01-13
BG65103B1 (bg) 2007-02-28
TR200101306T2 (tr) 2001-10-22
EE200100252A (et) 2002-10-15
PL204427B1 (pl) 2010-01-29
IL143023A0 (en) 2002-04-21
NL300373I2 (nl) 2009-04-01
BR9915552A (pt) 2001-08-14
US8003789B2 (en) 2011-08-23
DE69905683T2 (de) 2004-03-18
HRP20010161B9 (hr) 2014-10-24
NO20011696D0 (no) 2001-04-04
LTPA2008016I1 (lt) 2021-04-26
ATE233740T1 (de) 2003-03-15
HU227453B1 (en) 2011-06-28
LU91528I2 (fr) 2009-04-20
JP2002529456A (ja) 2002-09-10
JP3635238B2 (ja) 2005-04-06
CZ20011533A3 (cs) 2001-10-17
HRP20080359B1 (hr) 2016-01-01
NO20011696L (no) 2001-04-04
US8530655B2 (en) 2013-09-10
HK1048817B (en) 2010-04-09
US20080176880A1 (en) 2008-07-24
FR09C0004I2 (fr) 2010-06-11
EP1002795A1 (en) 2000-05-24
US6878717B2 (en) 2005-04-12
AU6200899A (en) 2000-05-29
AP1683A (en) 2006-11-29
UA70966C2 (uk) 2004-11-15
US7037917B2 (en) 2006-05-02
WO2000027825A1 (en) 2000-05-18
CY2008021I1 (el) 2010-07-28
AU2011200708A1 (en) 2011-03-10
AR024227A1 (es) 2002-09-25
HU230394B1 (hu) 2016-04-28
DE122009000003I1 (de) 2009-05-20
CA2350801C (en) 2008-05-20
MY121108A (en) 2005-12-30
DE69941934D1 (de) 2010-03-04
OA11674A (en) 2005-01-12
HUP0104177A3 (en) 2003-01-28
BG105418A (en) 2001-11-30
HRP20010161B1 (en) 2009-03-31
CN1322198A (zh) 2001-11-14
NO318801B1 (no) 2005-05-09
EP1270560A1 (en) 2003-01-02
ZA200103769B (en) 2002-08-12
LU91528I9 (no) 2019-01-02
US20050288278A1 (en) 2005-12-29
NZ511116A (en) 2003-08-29
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
FR09C0004I1 (no) 2009-02-27
HRP20010161A2 (en) 2002-02-28
CA2350801A1 (en) 2000-05-18
ATE455107T1 (de) 2010-01-15
HUP0104177A2 (hu) 2002-03-28
AU762523C (en) 2004-02-12
US20110263625A1 (en) 2011-10-27
CN1214013C (zh) 2005-08-10
EE05086B1 (et) 2008-10-15
EA200100536A1 (ru) 2002-02-28
HRP20080359A2 (en) 2008-12-31
NO2021015I1 (no) 2021-03-29
IL169949A (en) 2011-02-28
EA004049B1 (ru) 2003-12-25
BRPI9915552B8 (pt) 2021-05-25
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
ID28376A (id) 2001-05-17
HK1025330A1 (en) 2000-11-10
LTC1002795I2 (lt) 2021-06-10
AU762523B2 (en) 2003-06-26
NL300373I1 (nl) 2009-03-02
SK6032001A3 (en) 2002-01-07
TWI238161B (en) 2005-08-21
KR100658489B1 (ko) 2006-12-18
US20040039005A1 (en) 2004-02-26
PL347586A1 (en) 2002-04-08
KR20010075235A (ko) 2001-08-09
CZ301367B6 (cs) 2010-02-03
EP1002795B1 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
NO2009003I2 (no) Etravirin
DE69829040D1 (de) Elektroplattierungschemie
DE59914158D1 (de) Metallocenmonohalogenide
ATE341990T1 (de) Sigmidoskop
DE59911453D1 (de) Aktivkohlefilter
DE59912371D1 (de) Gleitschalungsfertiger
DE69808145D1 (de) Tintenbehälternachfüllsystem
DE59902874D1 (de) Buchsenkontakt
DE59901560D1 (de) Retrograder tibianagel
DE69812868D1 (de) Flanschreformierungsanlage
DE59907306D1 (de) Fadenchangierung
DE59906931D1 (de) Exzenterzahnradgetriebe
DE59911683D1 (de) Fahrzeugschliessanlage
DE69811890D1 (de) Einzellenkalorimeter
ATE262513T1 (de) Benzoylpyridazine
DE59903966D1 (de) Exzenterzahnradgetriebe
DE59913393D1 (de) Fadenchangierung
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
DE69827358D1 (de) Weglenkungsverfahren
DE69820261D1 (de) Steuerventilanordnnung
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59908057D1 (de) Underdruckhandhabungseinrichung
DE69809804D1 (de) Notlaufgeländereifen
DE59807217D1 (de) Nadellager